Ventris Launches Next Generation Allocell AF Biologic

Ventris Medical announced the first use of Allocell® AF, a next generation osteoinductive fiber allograft.

Allocell AF was developed for enhanced intra-operative handling and increased biologic responsiveness at the defect site. Allocell AF is designed with broad, augmented bone fibers that maximize the surface area, allowing the fibers to better fill the defect site.

“The Allocell AF fiber technology is the latest addition to the Allocell family that was introduced to the market in 2019. We are very pleased to add Allocell AF, with its proprietary fiber architecture, to our premium line of orthobiologics focused on spine and orthopedic fusion procedures,” said Russell Cook, CEO of Ventris Medical. “The rapid hydration combined with lot testing for osteoinductive potential solves the two most basic needs for the operating surgeon – handling and efficacy.”